Immuneering Co. (NASDAQ:IMRX) Given Average Recommendation of “Moderate Buy” by Brokerages

Immuneering Co. (NASDAQ:IMRX) has received an average recommendation of “Moderate Buy” from the eight ratings firms that are currently covering the firm, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $13.50.

A number of analysts recently issued reports on the company. Oppenheimer reissued an “outperform” rating and set a $25.00 target price on shares of Immuneering in a research note on Tuesday, March 5th. Guggenheim reissued a “neutral” rating on shares of Immuneering in a research note on Thursday, March 14th. Jefferies Financial Group reissued a “hold” rating and set a $3.00 target price (down from $16.00) on shares of Immuneering in a research note on Friday, March 15th. Mizuho lowered their target price on Immuneering from $20.00 to $8.00 and set a “buy” rating for the company in a research note on Tuesday, April 2nd. Finally, Chardan Capital lowered their target price on Immuneering from $21.00 to $16.00 and set a “buy” rating for the company in a research note on Friday, March 15th.

Insiders Place Their Bets

In other Immuneering news, major shareholder Cormorant Asset Management, Lp sold 400,000 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $2.90, for a total transaction of $1,160,000.00. Following the completion of the transaction, the insider now owns 2,895,273 shares of the company’s stock, valued at approximately $8,396,291.70. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, major shareholder Cormorant Asset Management, Lp sold 400,000 shares of the stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $2.90, for a total value of $1,160,000.00. Following the completion of the sale, the insider now owns 2,895,273 shares of the company’s stock, valued at approximately $8,396,291.70. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Ann E. Berman acquired 57,965 shares of the business’s stock in a transaction dated Monday, March 18th. The stock was bought at an average cost of $2.13 per share, with a total value of $123,465.45. Following the acquisition, the director now owns 67,465 shares in the company, valued at approximately $143,700.45. The disclosure for this purchase can be found here. Insiders bought a total of 111,790 shares of company stock valued at $266,645 in the last quarter. 23.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Immuneering

Hedge funds have recently added to or reduced their stakes in the business. UBS Group AG acquired a new stake in Immuneering during the 1st quarter valued at $26,000. Tower Research Capital LLC TRC lifted its holdings in Immuneering by 296.1% during the 3rd quarter. Tower Research Capital LLC TRC now owns 3,248 shares of the company’s stock valued at $25,000 after purchasing an additional 2,428 shares during the last quarter. Citigroup Inc. lifted its holdings in Immuneering by 2,078.7% during the 2nd quarter. Citigroup Inc. now owns 6,536 shares of the company’s stock valued at $66,000 after purchasing an additional 6,236 shares during the last quarter. California State Teachers Retirement System acquired a new stake in Immuneering during the 2nd quarter valued at $68,000. Finally, Barclays PLC lifted its holdings in Immuneering by 56.1% during the 2nd quarter. Barclays PLC now owns 8,144 shares of the company’s stock valued at $82,000 after purchasing an additional 2,927 shares during the last quarter. Institutional investors and hedge funds own 67.65% of the company’s stock.

Immuneering Price Performance

Shares of IMRX stock opened at $1.92 on Tuesday. The stock has a market cap of $56.07 million, a PE ratio of -1.01 and a beta of -0.89. The stock has a 50-day moving average of $4.53 and a 200-day moving average of $5.86. Immuneering has a one year low of $1.89 and a one year high of $14.29.

Immuneering (NASDAQ:IMRX) last announced its quarterly earnings results on Friday, March 1st. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.06). As a group, research analysts anticipate that Immuneering will post -1.89 earnings per share for the current year.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.